Biotechnology company Scynexis, Inc., is reporting early but promising results from a phase 3 trial of a novel drug for treating invasive Candida auris infections.
Although vaccines for the plague have been tried for decades, they have given only transient protection, and can’t protect against all forms of the plague, such as pneumonic plague.
The US Biomedical Advanced Research and Development Authority (BARDA) collaborates with JLABS to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases.
Misdiagnosis of infection strains in hospitals is leading to a public health crisis, as doctors treat these infections unnecessarily and ineffectively with antibiotics. To tackle this, new precision medicine solutions are being tested.
Research demonstrates the feasibility of using type I CRISPR-Cas to effectively introduce a spectrum of long-range chromosomal deletions with a single RNA guide in human embryonic stem cells and HAP1 cells. Type I CRISPR systems rely on the multi-subunit ribonucleoprotein (RNP) complex Cascade to identify DNA targets and on the helicase-nuclease enzyme Cas3 to degrade DNA processively.
A pig carcass which washed up on the shore in Kinmen County has tested positive for African swine fever (ASF), the third such case reported in the county, announced Taiwan's Central Emergency Operation Center for ASF on Wednesday, April 10.
The decision to scrap the World Pork Expo, held by the National Pork Producers Council in Des Moines each June, signals growing fears about the spread of African swine fever in Asia.
The surge in new Ebola cases in the Democratic Republic of the Congo (DRC) continued at a brisk pace Tuesday, April 9, with 14 new cases reported from a broad range of larger and smaller hot spots, the health ministry said in its daily statement.
The Ebola virus causes a disease that kills up to 90 percent of those who contract it, but a promising vaccine could provide protection.
The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.